Sernova Biotherapeutics Inc (TSX:SVA)
Canada · Delayed Price · Currency is CAD 0.0900
0.00 (0.00%)
Sep 25, 2026, 2:08 PM EST
Sernova Biotherapeutics Balance Sheet
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Cash & Equivalents | 0.06 | 0.27 | 6.01 | 8.72 | 3.78 | 27.87 |
Short-Term Investments | - | - | - | 11.08 | 46 | - |
Cash & Short-Term Investments | 0.06 | 0.27 | 6.01 | 19.81 | 49.78 | 27.87 |
Cash Growth | -24.26% | -95.59% | -69.64% | -60.21% | 78.57% | 605.78% |
Other Receivables | 0.01 | 0.12 | 0.3 | 1.05 | 1.15 | 0.45 |
Receivables | 0.01 | 0.12 | 0.3 | 1.05 | 1.15 | 0.45 |
Prepaid Expenses | 0.3 | 0.14 | 0.16 | 0.16 | 0.17 | 0 |
Total Current Assets | 0.37 | 0.52 | 6.47 | 21.02 | 51.09 | 28.33 |
Property, Plant & Equipment | 0 | 0.02 | 0.83 | 0.51 | 0.65 | 0.56 |
Other Intangible Assets | - | - | - | 0.32 | 0.52 | 0.72 |
Other Long-Term Assets | - | 0.22 | 0.22 | 0.26 | 0.22 | 0.21 |
Total Assets | 0.37 | 0.76 | 7.53 | 22.11 | 52.48 | 29.82 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Accounts Payable | 5.11 | 17.67 | 17.24 | 6.85 | 3.61 | 0.38 |
Accrued Expenses | 4.44 | 3.4 | 2.67 | 2.51 | 0.99 | 0.91 |
Short-Term Debt | - | 3.73 | - | - | - | - |
Current Portion of Leases | - | - | 0.1 | 0.14 | 0.14 | 0.12 |
Other Current Liabilities | - | - | - | 0.1 | - | 0.07 |
Total Current Liabilities | 12.05 | 24.8 | 20.02 | 9.59 | 4.74 | 1.48 |
Long-Term Debt | 0.08 | 1.04 | - | - | - | - |
Long-Term Leases | - | - | 0.47 | - | 0.14 | 0.28 |
Total Liabilities | 12.13 | 25.84 | 20.48 | 9.59 | 4.88 | 1.75 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Common Stock | 125.26 | 118.7 | 116.68 | 110.99 | 110.99 | 74.01 |
Additional Paid-In Capital | 23.41 | 21.79 | 20.69 | 19.69 | 12.49 | 5.11 |
Retained Earnings | -174.19 | -166.1 | -150.36 | -118.17 | -79.17 | -54.75 |
Comprehensive Income & Other | 1.74 | 0.54 | 0.03 | - | 3.3 | 3.69 |
Shareholders' Equity | -11.75 | -25.08 | -12.96 | 12.51 | 47.61 | 28.07 |
Total Liabilities & Equity | 0.37 | 0.76 | 7.53 | 22.11 | 52.48 | 29.82 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Total Debt | 2.58 | 4.77 | 0.57 | 0.14 | 0.28 | 0.39 |
Net Cash (Debt) | -2.52 | -4.51 | 5.44 | 19.67 | 49.5 | 27.48 |
Net Cash Growth | - | - | -72.33% | -60.26% | 80.13% | 746.40% |
Net Cash Per Share | -0.01 | -0.01 | 0.02 | 0.06 | 0.18 | 0.11 |
Filing Date Shares Outstanding | 377.64 | 336.7 | 328.48 | 303.33 | 303.33 | 262.26 |
Total Common Shares Outstanding | 377.64 | 332.85 | 325.32 | 303.33 | 303.33 | 261.13 |
Working Capital | -11.68 | -24.27 | -13.55 | 11.43 | 46.35 | 26.85 |
Book Value Per Share | -0.06 | -0.08 | -0.04 | 0.04 | 0.16 | 0.11 |
Tangible Book Value | -23.78 | -25.08 | -12.96 | 12.2 | 47.09 | 27.35 |
Tangible Book Value Per Share | -0.06 | -0.08 | -0.04 | 0.04 | 0.16 | 0.10 |
Machinery | - | 0.21 | 0.9 | 0.9 | 0.8 | 0.47 |